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Abstract
The easy accessibility of skin makes it an excellent target for gene transfer protocols. To take full advantage of
skin as a target for gene transfer, it is important to establish an efficient and reproducible delivery system.
Electroporation is a strong candidate to meet this delivery criterion. Electroporation of the skin is a simple, direct,
in vivo method to deliver genes for therapy. Previously, delivery to the skin was performed by means of
applicators with relatively large distances between electrodes, resulting in significant muscle stimulation and
pain. These applicators also had limitations in controlling the directionality of the applied field. To resolve this
issue, a system consisting of an array of electrodes that decreased the distance between them and that were
independently addressable for directional control of the field was developed. This new multielectrode array
(MEA) was compared with an established electrode. In a rat model, comparable reporter expression was seen
after delivery with each electrode. Delivery was also evaluated in a guinea pig model to determine the potential
of this approach in an animal model with skin thickness and structure similar to human skin. The results clearly
showed that effective delivery was related to both the electrode and the parameters chosen. With the MEA, the
muscle twitching associated with application of electric fields was notably reduced compared with conventional
electrode systems. This is important, as it will facilitate the translation of electroporation-mediated gene delivery
to skin for clinical use with DNA vaccines or for therapies for cancer or protein deficiencies.
Introduction
The skin is an attractive target for gene medicine, partic-ularly for applications pertaining to cutaneous diseases,
vaccines, and some metabolic disorders. It is easily accessible
for both delivery and monitoring. As with any gene transfer
approach, it is essential to develop a reliable delivery system.
Electroporation is an effective means of delivering plasmid
DNA to many tissues in vivo (Heller and Heller, 2006). Several
studies have shown that electroporation efficiently delivers
plasmid DNA to the skin, increasing local and serum ex-
pression levels compared with injection alone (Titomirov et al.,
1991; Glasspool-Malone et al., 2000; Dujardin et al., 2001;
Heller et al., 2001, 2007, 2008; Maruyama et al., 2001; Chesnoy
and Huang, 2002; Babiuk et al., 2003; Medi et al., 2005; Pavselj
and Preat, 2005). Skin electroporation delivery has been suc-
cessfully performed in rodent, porcine, and nonhuman pri-
mate model systems (Glasspool-Malone et al., 2000).
Electroporation of skin is a simple delivery method for
prophylactic or therapeutic gene therapy applications. A key
component of delivery is the electrode applicator used to
apply the electric fields. Current electrode systems are cum-
bersome and typically induce significant muscle twitching
and discomfort. This is related to the distance between the
electrodes and the applied voltage. The current designs are
also limited with respect to expandability, and the number of
addressable electrode pairs that are contained within the
electrode applicator is also limited, which impacts the direc-
tional control of the fields.
This brief report describes an approach that could over-
come these limitations. A multielectrode array (MEA) ap-
plicator (Fig. 1) was developed. With the MEA, the applied
voltage is minimized by maintaining a short electrode dis-
tance. By reducing the distance between the electrodes, the
area of tissue affected by each electric pulse and the depth of
penetration of the field are reduced as well. This diminishes
or eliminates the muscle twitching and sensation (discom-
fort) associated with the application of the pulsed electric
fields. In addition, the electrodes within the applicator are
independently addressable for directional control of the field.
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Finally, the treatment area can eventually be expanded by
the addition of rows of electrodes to the array. In this way,




gWizLuc was commercially prepared (Aldevron, Fargo,
ND). Endotoxin levels were <0.1 EU=mg plasmid.
Animals
Female Hartley guinea pigs (250–300 g) or male Sprague
Dawley rats (200–250 g) were used in this study. All animals
were anesthetized in an induction chamber charged with 3%
isoflurane in O2 and then fitted with a standard rodent mask
and kept under general anesthesia during treatment.
Electroporation procedure
Animals received an intradermal injection of gWizLuc
(2 mg=ml) in sterile injectable saline via the abdomen (rat) or
FIG. 1. Multielectrode array (MEA). (A) The novel multielectrode array was constructed by embedding 16 gold-plated
posts, approximately 0.3 mm in diameter, into a flat Teflon disk. The electrodes were embedded so that their circular ends
protruded approximately 300 mm from the disk end. The disk was placed in a handle for ease of use. Electrodes are numbered
1–16 to facilitate description of the pulsing sequence explained in Materials and Methods. (B) Illustration depicting the firing
sequence. Arrows indicate the active electrodes and four pulses were applied each time. Direction and=or active electrodes
change for each set of four pulses. Following sequence H the pattern continues according to the same pattern until all elec-
trodes have been fired, which includes nine 2-mm squares. Color images available online at www.liebertonline.com=hum.
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flank (guinea pig) followed immediately by administration
of electric pulses. For those groups receiving electric pulses
with the 4PE, the electrode was placed around the injection
site and two sets of four pulses in perpendicular directions
were administered as previously described (Heller et al.,
2007, 2008). The 4PE consists of four stainless steel plates
(3.5 mm wide) that are insulated except for 2–3 mm at the
bottom of each inside face. The four plates are situated
around a nonconductive ‘‘stopper’’ that orients the plates to
form a 66 mm square. This allows the 4PE to be placed
around a 6-mm-diameter area formed after the 50-ml injec-
tion. In addition, this orientation allows pulses to be applied
in two electric field orientations at a 908 angle. For those
groups receiving electric pulses with the MEA, the applicator
was placed over the injection site and pulses were applied
via groups of four electrodes. The firing sequence covered a
series of 22 mm squares and was fired as follows (Fig. 1B): 1
and 5 to 2 and 6; 1 and 2 to 5 and 6; 5 and 9 to 6 and 10; 5 and
6 to 9 and 10; 9 and 13 to 10 and 14; 9 and 10 to 13 and 14; 2
and 6 to 3 and 7; 2 and 3 to 6 and 7, and so on. The electric
pulses were generated with a high-voltage power supply
(HV Rack, 1=4C24-P250; Ultravolt, Ronkonkoma, NY). The
applied voltage was controlled by the high-voltage power
supply, whereas pulse width, pulse frequency, and pulsing
sequence were controlled by a customized program using
LabVIEW 8.2.1 (National Instruments, Austin, TX). The ap-
plied voltages were varied as described.
Luciferase reporter assay
At the indicated time points after plasmid delivery, lucif-
erase activity was quantified as previously described (Heller
et al., 2000). Activity was expressed as total nanograms of
luciferase per tissue sample. Statistical analysis was per-
formed by Kruskal–Wallis nonparametric analysis of vari-
ance. Group differences were compared by Dunn’s multiple
comparisons test.
Histological analysis
Forty-eight hours after treatment, guinea pigs were killed
and the 6-mm-diameter treated area was removed. Each
sample was fixed and four sections were stained with he-
matoxylin and eosin and then examined histologically for
damage. Samples were graded for percent damage, using a
schema including surface damage (burning and=or necrosis)
and subepidermal necrosis (Heller et al., 2007). The total
amount of damage (surface and subepidermal area affected)
was determined as a percentage of the total treatment area.
Results and Discussion
Delivery of plasmid DNA to the skin by electroporation
was previously evaluated in both mouse and rat skin, using
a specially constructed electrode (4PE; see Materials and
Methods) (Heller et al., 2007, 2008). Skin delivery has been
performed with caliper electrodes as well. Although cuta-
neous delivery was successful and high levels of expression
were achieved, these electrode designs have some draw-
backs. First, the field is developed across a small set of an-
odes and cathodes that are kept a specific distance apart.
With the exception of relatively small surface areas, these
designs prevent optimal interaction of the applicator with
the target tissue. Second, the nature of these electrode de-
signs produces excessive distance between the electrode
pairs, which requires additional voltage to create the desired
field strength. Thus, the administration of electric pulses re-
sults in significant muscle stimulation. This stimulation has
been associated with pain or discomfort in clinical studies
(Zhang and Rabussay, 2002; Wong et al., 2006; Zupanic et al.,
FIG. 2. Comparison of MEA and 4PE in Sprague Dawley rats. Intradermal injection of gWizLuc plasmid (50ml, 2 mg=ml)
was performed via the abdomen. Electroporation was performed with either the 4PE or MEA under the specified conditions.
Columns and error bars represent the mean of the means and standard error of the means for three replicate experiments of
four samples each. **p< 0.01 compared with injection alone. Pþ, injection with gWizLuc; E, no electroporation; Eþ,
electroporation administered.
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2007; Daud et al., 2008; Bodles-Brakhop et al., 2009; Wallace
et al., 2009). This becomes an important issue, particularly if
it is necessary to treat a large area to obtain therapeutic levels
of a delivered transgene. To reduce the sensation associated
with the administration of electric pulses through the elec-
trodes, another electrode configuration was developed and
tested. The MEA (Fig. 1) contained 16 electrodes configured in
4 rows of 4 electrodes with a 2-mm electrode separation. The
electrodes within the MEA are independently addressable
and thus can be administered in specific pulsing patterns.
Intradermal delivery of a plasmid encoding luciferase was
used to evaluate the effectiveness of this new design in a
Sprague Dawley rat model (Fig. 2). Several electroporation
parameters, based on previous results with the 4PE, were
tested and the levels of expression compared with delivery
with the 4PE (four pulses applied in two perpendicular di-
rections for a total of eight pulses). The pulsing pattern of the
MEA was similar to the 4PE, with separate pulses applied in
perpendicular directions between each group of four elec-
trodes. Four pulses were administered between each of the
anode–cathode pairs (two perpendicular directions for a total
of eight pulses) in a series of 2-mm squares as described
in Materials and Methods. The MEA contains a total of nine
2-mm squares and therefore a complete MEA sequence in-
cluded 72 pulses.
These results show that both electrode configurations can
effectively deliver this reporter plasmid. All electroporation
conditions tested with both electrodes showed significantly
FIG. 3. Delivery of gWizLuc to Hartley guinea pig skin with MEA and 4PE. Intradermal injection of gWizLuc plasmid
(50 ml, 2 mg=ml) was performed via the flank. (A) Electroporation was performed with the MEA or 4PE at the specified field
strengths and pulse widths. Columns and error bars represent the mean of the means and standard error of the means for
three replicate experiments. **p< 0.01, comparing the MEA with injection alone or 4PE. Pþ, injection with gWizLuc; E, no
electroporation; Eþ, electroporation administered. (B) Electroporation was performed with the MEA at the specified field
strengths at a pulse width of 150 msec. Columns and error bars represent the mean of the means and standard error of the
means. For 250 and 300 V=cm there were eight replicate experiments; for 200 V=cm there were four replicate experiments; and
for 350 V=cm there were three replicate experiments of four samples each. *p< 0.05; **p< 0.01 when compared with injection
alone (eight replicate experiments).
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higher expression than injection of plasmid without electro-
poration. In addition, both the 4PE pulsing conditions and
the 300 V=cm, 150 msec pulsing conditions with the MEA
were significantly higher than the levels obtained with the
MEA at 100 V=cm and 300 msec. These results suggest that
the applied electric field strength is an important consider-
ation, because comparable expression was obtained with
increased field strength, but not with increased pulse dura-
tion. Although it was necessary to increase the field strength
to achieve comparable expression patterns with the MEA,
muscle stimulation during pulse administration was greatly
reduced or eliminated with the MEA applicator when com-
pared with the pronounced muscle contractions seen with
the 4PE and caliper electrodes. Although this is not testable
in animals, this suggests that the potential discomfort asso-
ciated with delivery using this electrode design would be
reduced or eliminated.
To better simulate delivery to skin similar in thickness to
human skin, a second series of experiments to test the MEA
was performed with guinea pigs. Expression in guinea pig
skin, using parameters of 300 V=cm and 150 msec (Fig. 3A),
was higher than that observed in rat skin ( p< 0.01) when
using the MEA and the same pulsing conditions. Interest-
ingly, expression levels obtained with the 4PE and the same
parameters as with rat skin were greatly reduced. Expression
levels obtained with the MEA were significantly higher
( p< 0.01) than those obtained with the 4PE or injection only
(Fig. 3A). As was seen in the rat studies, there was a greatly
reduced level of muscle twitching with the MEA compared
with the 4PE. The effect of varying the field strength with the
MEA was also evaluated. Delivery of plasmid with applied
field strengths of 250, 300, and 350 V=cm at a pulse width of
150 msec resulted in significantly higher expression than in-
jection of plasmid without electroporation (Fig. 3B). Expres-
sion levels did not significantly differ between these three
groups. Delivery of plasmid with an applied field strength of
200 V=cm at a pulse width of 150 msec did not result in
significantly higher expression than injection of plasmid
without electroporation.
In addition to expression levels, it was also critical to de-
termine whether delivery with the MEA caused damage to
the skin. The delivery was repeated using injection of plas-
mid alone, injection of plasmid with electroporation at
300 V=cm and 150 msec, or injection of saline without elec-
troporation (four samples for each group). Guinea pigs were
killed 48 hr after the procedure and the treated area was re-
moved for histological evaluation. Minimal to no damage
was seen in the guinea pigs receiving plasmid and saline
injection. Less than 5% damage was seen in the electro-
porated samples. These results are similar to what was re-
ported previously when delivery was performed to mouse
skin (Heller et al., 2007).
Electroporation is a powerful tool for use in nonviral gene
therapy. Efficient and effective delivery has been accom-
plished preclinically to a variety of tissues and for multiple
therapeutic applications (Heller and Heller, 2006; Bodles-
Brakhop et al., 2009). The first clinical trials using this de-
livery approach for gene therapy have been initiated. The
results from the first trial have been reported and demon-
strate the effectiveness of this approach in the delivery of the
immune modulator interleukin-12 to melanomas (Daud et al.,
2008). The results presented here show that effective delivery
of plasmid DNA can be accomplished with a multielectrode
array. This array was designed to maintain the distance be-
tween electrodes independent of the actual delivery area,
minimizing the applied voltage needed for delivery. Al-
though a higher applied field at the same applied voltage
was needed compared with a standard electrode, the muscle
twitching associated with application of electric fields was
observed to be drastically reduced. These improvements to
the electrode applicator will facilitate the translation of
electroporation-mediated gene delivery to the clinic for use
with DNA vaccines or for therapies for cancer or protein
deficiencies.
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